Biotech Values

[iwfal]

From everything I've read, 400mg a day is a very sub-optimal dose. And it wasn't given long enough. And it didn't combine HCQ with Azithromycin. If they can get some decent results with this protocol, I think it is safe to assume that a better protocol will produce even better results.

All I’ll state is what I’ve said before these results came out:

1) that I’ve always thought the best shot was a lower dose given earlier in the disease and was worth running well controlled trials (but note that for no specific drugs, including this one, do I give particularly high odds. That’s why I wouldn’t want too much focus on any one drug, including this one, until pretty conclusively proven)

2) because:
2a) high doses have toxicity (that might not mean much in most well people, but this disease really picks on those with comorbidities)
2b) when treating the virus itself, earlier is much better. Later seems to be hopeless for acute anti viral treatment - eg in this disease the really bad phases are driven more by hyper immune activation more than virus itself.

As for Azithromycin, I give low odds it is helpful except as prophylaxis to ward off opportunistic bacterial infections. So actually may be better later in disease than earlier.